A Phase 1 interventional study of PF-06863135 monotherapy IV or SC and PF-06863135 + dexamethasone in Multiple Myeloma, sponsored by Pfizer. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.
Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 1, and was the 1st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Celgene · Sites in United States, Canada, China and 5 more countries
Ages 18+
University of Miami · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 5 · Phase 4 2
First in 2017; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 75 across the 31 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Multiple Myeloma by Pfizer: 6 open now, 12 under way, 4 of them phase 3. Of 30 finished, 14 (47%) have results posted.
Among the 44 studies in Multiple Myeloma by Pfizer, this one is the 11th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2017, is one of 16 in phase 1, and was the 15th registered.
Pfizer’s Multiple Myeloma studies by the year they started, since 1999.
7 of the studies testing elranatamab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT06421675Ontario Clinical Oncology Group (OCOG)Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | 2026-12 |
| NCT06832865Massachusetts General HospitalELISA in Relapsed/Refractory MM | 2026-12-01 |
| NCT06015542Thomas LundSelf-administration of Subcutaneous Elranatamab in the Patients' Homes. | 2026-12-01 |
| NCT06988488CelgeneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 31 studies testing elranatamab in Multiple Myeloma, from their registry updates:
Among Pfizer’s 44 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Study C1071001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic study of PF-06863135 in adult patients with advanced multiple myeloma who have relapsed from or are refractory to standard therapy. This is a two part study; Part 1 will assess the safety and tolerability of increasing dose levels of PF-06863135 and Part 2 will evaluate safety and anti-myeloma activity of PF-06863135 at the RP2Ds determined in Part 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BCMA-CD3 bispecific antibody
Drug: PF-06863135 monotherapy IV or SC
BCMA-CD3 bispecific antibody + dexamethasone
Drug: PF-06863135 + dexamethasone
BCMA-CD3 bispecific antibody + lenalidomide
Drug: PF-06863135 + lenalidomide
BCMA-CD3 bispecific antibody + pomalidomide
Drug: PF-06863135 + pomalidomide
PF-06863135 will be administered intravenously or subcutaneously.
Also known as: BCMA-CD3 bispecific antibody
Drug pages: Elranatamab · Dexamethasone
PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
Also known as: BCMA-CD3 bispecific antibody + dexamethasone
Drug pages: Elranatamab · Lenalidomide
PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
Also known as: BCMA-CD3 bispecific antibody + lenalidomide
Drug pages: Elranatamab · Pomalidomide
PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
Also known as: BCMA-CD3 bispecific antibody + pomalidomide
Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v)4.03
Hematological: Grade 4 neutropenia lasting \>5 days; Febrile neutropenia \<1000/mm\^3 with a single temperature of \>38.3 degree Celsius (C) or a sustained temperature of \>=38 degree C for more than one hour; grade \>=3 neutropenia with infection; grade 4 thrombocytopenia; grade 3 thrombocytopenia with \>= Grade 2 bleeding. Non-hematological: grade 4 adverse events (AEs); Grade 3 AE lasting \>=5 days despite optimal supportive care, with exception of AE attributed to cytokine release syndrome (CRS) event; grade 3 CRS, except those CRS that had a) not been maximally treated or b) improved to \<=grade 1 within 48 hours; grade 4 CRS; confirmed drug-induced liver injury (DILI) meeting Hy's law criteria; grade 4 laboratory abnormalities deemed clinically significant by the investigator reported Grade 4 AE; clinically important or persistent toxicities that were not included in above criteria were also be considered a DLT following review by the investigators and the sponsor.
Time frame: Cycle 1 (21 Days)
Part 2: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria
ORR per IMWG criteria: percentage of participants with best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). sCR: complete response plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein and reduction in 24 hrs urinary M-protein by \>=90% or to \<200 mg/24 hr. If serum and urine M-protein were unmeasurable, \>=50% decrease in difference between involved and uninvolved FLC levels required in place of the M-protein criteria.
Time frame: From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)
Part 2: Duration of Response (DOR) as Per IMWG Criteria
DOR per IMWG criteria:time from first documentation of objective tumor (OT)response to first documentation of OTprogression or to death due to any cause, whichever occurred first.sCR: CR plus normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry;CR:Negative immunofixation on serum \& urine \& disappearance of any soft tissue plasmacytomas\&\<5% plasma cells in bone marrow aspirates.VGPR: serum \& urine M-protein(Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hrs urinary Mp by \>=90% or to \<200 mg/24 hr.If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It did not include second primary malignancies of unrelated types.
Time frame: From the first documentation of objective tumor response to first documentation of objective tumor progression or new anti-cancer therapies or death, whichever occurred first, (maximum up to 34.3 months)
Part 1: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious AEs, Treatment Related AEs, Grade 3 or 4 AEs and Grade 5 AEs as Graded by NCI CTCAE v4.03
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to intervention. TEAE: any event increasing in severity from baseline or event started during PF-06863135 therapy or within 30 days of last dose of drug. SAE: any untoward medical occurrence at any dose that resulted in either: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via Pfizer product of infectious agent, pathogenic or non-pathogenic; or considered as important event. Treatment-related AE: AEs attributed to drug in participants who received drug. Relatedness was judged by investigator. NCI CTCAE v4.03, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. AEs included SAEs and all non-SAEs.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 43.3 months)
Part 1: Number of Participants With Shifts From Grade Less Than or Equal to (<=) 2 at Baseline to Grade 3 or 4 Post-Baseline in Hematology Parameters
Hematology parameters included: activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and, white blood cell decreased. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of hematology parameters are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 43.3 months)
Part 1: Number of Participants With Shifts From Grade <= 2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Chemistry Parameters
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of clinical chemistry parameters are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 43.3 months)
Part 1: Number of Participants With Shifts From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Urinalysis
Proteinuria was estimated in urinalysis. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of urinalysis parameters are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 43.3 months)
Part 1: ORR as Per IMWG Criteria
ORR per IMWG criteria: percentage of participants with best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). sCR: complete response plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein and reduction in 24 hrs urinary M-protein by \>=90% or to \<200 mg/24 hr. If serum and urine M-protein were unmeasurable, \>=50% decrease in difference between involved and uninvolved FLC levels required in place of the M-protein criteria.
Time frame: From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 63.31 months)
Part 1: Time to Response (TTR) as Per IMWG Criteria
TTR: Defined for participants with confirmed objective response as time from first dose to first documentation of objective tumor response. sCR: complete response + normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum\& urine \& disappearance of soft tissue plasmacytomas \& \<5% plasma cells in bone marrow aspirates. VGPR: serum\& urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein\& reduction in 24hrs urinary M-protein by \>=90% or \<200 mg/24hr. If serum \& urine M-protein unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of M-protein criteria. Progression: Appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
Time frame: From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 63.31 months)
Part 1: Complete Response Rate (CRR) as Per IMWG Criteria
CRR: percentage of participants with complete response (sCR or CR). sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
Time frame: From the first dose of study treatment until the first documented sCR or CR or new anti-cancer therapies or death, whichever occurred first (maximum up to 63.31 months)
Part 1: DOR as Per IMWG Criteria
DOR per IMWG criteria:time from first documentation of objective tumor (OT)response to first documentation of OTprogression or to death due to any cause, whichever occurred first.sCR: CR plus normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry;CR:Negative immunofixation on serum \& urine \& disappearance of any soft tissue plasmacytomas\&\<5% plasma cells in bone marrow aspirates.VGPR: serum \& urine M-protein(Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hrs urinary Mp by \>=90% or to \<200 mg/24 hr.If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It did not include second primary malignancies of unrelated types.
Time frame: From the first documentation of objective tumor response to first documentation of objective tumor progression or new anti-cancer therapies or death, whichever occurred first, (maximum up to 63.31 months)
Part 1: Duration of Complete Response (DoCR) as Per IMWG Criteria
DoCR was defined for participants with confirmed complete response (sCR or CR) as the time from the first documentation of complete response to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. Progression was defined as appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
Time frame: From the first documentation of complete response to the first documentation of tumor progression or death, whichever occurred first (maximum up to 63.31 months)
Part 1: Duration of Stable Disease (DOSD) as Per IMWG Criteria
DOSD per IMWG criteria: participants with confirmed stable disease (SD): time from first documentation (doc) of objective SD to first doc of objective tumor progression (P)/death by any cause, whichever occurred first. SD: not meeting criteria for CR,VGPR, PR, MR or PD. CR: Negative immunofixation on serum \& urine \&disappearance of any soft tissue plasmacytomas \&\<5% plasma cells in bone marrow aspirates. VGPR: serum \& urine M-protein (Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hours urinary Mp by \>=90% or\<200 mg/24 hr. If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
Time frame: Time from the first documentation of objective stable disease to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first (maximum up to 63.31 months)
Part 1: Progression Free Survival (PFS) as Per IMWG Criteria
PFS as per IMWG criteria was the time from start date of study treatment to date of first documentation of progression, or death due to any cause. Progression was defined as the appearance of local, regional or distant disease of the same type after CR or progression of pre-existing lesions. It does not include second primary malignancies of unrelated types. CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
Time frame: From start date of study treatment to date of first documentation of progression or death due to any cause, whichever occurred first (maximum up to 63.31 months)
Part 1: Overall Survival (OS)
OS was defined as the time from start date of study treatment to date of death due to any cause. OS for participants not known to had died were censored on the date of last known alive.
Time frame: Time from start date of study treatment to date of death due to any cause or last-known-alive date, whichever occurred first (maximum up to 63.31 months)
Part 1: Percentage of Participants With Negative Minimal Residual Disease (MRD) Using IMWG MRD Criteria
MRD negativity rate: percentage of participants with negative MRD (assessed by central laboratory) per IMWG criteria at any time from date of first dose until first documentation of confirmed progression, death or start of new anticancer therapy, whichever occurred first. Progression was defined as appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types. MRD negativity was defined by two thresholds, 10\^-5 and 10\^-6.
Time frame: Anytime from date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurred first (maximum up to 63.31 months)
Part 1: Maximum Observed Concentration (Cmax) of PF-06863135
Cmax of PF-06863135 was measured in this outcome measure. Total is free and bound drug in the body.
Time frame: 0 hours (h) on Day 1 of Cycle (C) 0; 0, 2 and 4h on Day 1 of C1 and C2
Part 1: Area Under the Concentration-Time Profile From Time 0 to End of Dosing Interval (AUCtau)
Area under the concentration curve from time 0 to end of dosing interval (AUCtau) was measured in this outcome measure. Total is free and bound drug in the body.
Time frame: 0 hours (h) on Day 1 of Cycle (C) 0; 0, 2 and 4h on Day 1 of C1 and C2
Part 1C and Part 1D: Plasma Concentration of Lenalidomide and Pomalidomide
Plasma concentration of lenalidomide and pomalidomide was measured in this outcome measure.
Time frame: Cycle 1 (0 hours post dose on Day 1, 8 and 15); Cycle 2 (0 hours on Day 15)
Part 1: Number of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF-06863135
Number of participants with ADA and NAb against PF-06863135 were reported in this outcome measure. A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-folder dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: From first dose of the study treatment (Day 1) up to end of study treatment (maximum up to 63.31 months)
Part 1: Concentration of Soluble Cytokines in Serum
The concentration of Interleukin-2, Interleukin-6, Interferon-gamma and tumor necrosis factor-alpha were measured in this outcome measure. Cycle = C.
Time frame: Part 1: C1 (0, 2, 4 & 8 hours [h] post dose on Day [D] 1, 24h post dose on D2, 72h post dose on D3); Part 1.1, 1C & 1D: C0 (0, 2, 4 & 8h post dose on D1, 24h post dose on D2); C1 (0, 2, 4 & 8h post dose on D1, 24h post dose on D2, 72h post dose on D3)
Part 2: Number of Participants With AEs, Serious AEs, Treatment Related AEs, Grade 3 or 4 AEs and Grade 5 AEs as Graded by NCI CTCAE v4.03
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to intervention. TEAE: any event increasing in severity from baseline or event started during PF-06863135 therapy or within 30 days of last dose of drug. SAE: any untoward medical occurrence at any dose that resulted in either: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via Pfizer product of infectious agent, pathogenic or non-pathogenic; or considered as important event. Treatment-related AE: AEs attributed to drug in participants who received drug. Relatedness was judged by investigator. NCI CTCAE v4.03, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. AEs included SAEs and all non-SAEs.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 32.3 months)
Part 2: Number of Participants With Shifts From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Hematology Parameters
Hematology parameters included: activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and, white blood cell decreased. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of hematology parameters are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 32.3 months)
Part 2: Number of Participants With Shifts From Grade <= 2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Chemistry Parameters
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of clinical chemistry parameters are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 32.3 months)
Part 2: Number of Participants With Shifts From Grade <=2 to Grade 3 or 4 Post-Baseline in Urinalysis
Proteinuria was estimated in urinalysis. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of urinalysis parameters are reported.
Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to of 32.3 months)
Part 2: CRR as Per IMWG Criteria
CRR: percentage of participants with complete response (sCR or CR). sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
Time frame: From the first dose of study treatment until the first documented sCR or CR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)
Part 2: DoCR as Per IMWG Criteria
DoCR was defined for participants with confirmed complete response (sCR or CR) as the time from the first documentation of complete response to the first documentation of objective tumor progression or to death due to any cause, whichever occured first. sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. Progression was defined as appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
Time frame: From the first documentation of complete response to the first documentation of tumor progression or death, whichever occurred first (maximum up to 34.3 months)
Part 2: TTR as Per IMWG Criteria
TTR: Defined for participants with confirmed objective response as time from first dose to first documentation of objective tumor response. sCR: complete response + normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum\& urine \& disappearance of soft tissue plasmacytomas \& \<5% plasma cells in bone marrow aspirates. VGPR: serum\& urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein\& reduction in 24hrs urinary M-protein by \>=90% or \<200 mg/24hr. If serum \& urine M-protein unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of M-protein criteria. Progression: Appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
Time frame: From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 34.3 months)
Part 2: DOSD as Per IMWG Criteria
DOSD per IMWG criteria: participants with confirmed stable disease (SD): time from first documentation (doc) of objective SD to first doc of objective tumor progression (P)/death by any cause, whichever occurred first. SD: not meeting criteria for CR,VGPR, PR, MR or PD. CR: Negative immunofixation on serum \& urine \&disappearance of any soft tissue plasmacytomas \&\<5% plasma cells in bone marrow aspirates. VGPR: serum \& urine M-protein (Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hours urinary Mp by \>=90% or\<200 mg/24 hr. If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
Time frame: Time from the first documentation of objective stable disease to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first (maximum up to 34.3 months)
Part 2: PFS as Per IMWG Criteria
PFS as per IMWG criteria was the time from start date of study treatment to date of first documentation of progression, or death due to any cause. Progression was defined as the appearance of local, regional or distant disease of the same type after CR or progression of pre-existing lesions. It does not include second primary malignancies of unrelated types. CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
Time frame: From start date of study treatment to date of first documentation of progression or death due to any cause, whichever occurred first (maximum up to 34.3 months)
Part 2: OS
OS was defined as the time from start date of study treatment to date of death due to any cause. OS for participants not known to had died were censored on the date of last known alive.
Time frame: Time from start date of study treatment to date of death due to any cause or last-known-alive date, whichever occurred first (maximum up to 34.3 months)
Part 2: Percentage of Participants With Negative MRD After Treatment With PF-06863135 Using IMWG MRD Criteria
MRD negativity rate: percentage of participants with negative MRD (assessed by central laboratory) per IMWG criteria at any time from date of first dose until first documentation of confirmed progression, death or start of new anticancer therapy, whichever occurred first. Progression was defined as appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types. MRD negativity was defined by two thresholds, 10\^-5 and 10\^-6.
Time frame: Anytime from date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy whichever occurred first (maximum up to 34.3 months)
Part 2: Number of Participants With ADA and NAb Against PF-06863135
Number of participants with ADA and NAb against PF-06863135 were reported in this outcome measure. A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-folder dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: From first dose of the study treatment (Day 1) up to end of study treatment (maximum up to 34.3 months)
Part 2: Concentration of Soluble Cytokines in Serum
The concentration of Interleukin-2, Interleukin-6, Interferon-gamma and tumor necrosis factor-alpha were measured in this outcome measure.
Time frame: Cycle 0 (0, 2, 4 and 8 hours post dose on Day 1, 24 hours post dose on Day 2); Cycle 1 (0, 2, 4 and 8 hours post dose on Day 1, 24 hours post dose on Day 2, 72 hours post dose on Day 3)
A total of 101 participants (Part 1: 86 participants and Part 2: 15 participants) were enrolled in the study.
| Milestone | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 3 | 2 | 3 | 2 | 5 | 6 | 6 | 4 | 4 | 4 | 6 | 6 | 7 | 13 | 4 | 9 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 3 | 2 | 3 | 2 | 5 | 6 | 6 | 4 | 4 | 4 | 6 | 6 | 7 | 13 | 4 | 9 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 1 | 1 | 0 |
| Withdrew: Refused further treatment | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 0 |
| Withdrew: Disease relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 2 | 3 | 2 | 3 | 2 | 5 | 3 | 5 | 3 | 1 | 2 | 2 | 3 | 3 | 8 | 3 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 1 | 0 |
| Milestone | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Refused further treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Disease relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Hematological: Grade 4 neutropenia lasting \>5 days; Febrile neutropenia \<1000/mm\^3 with a single temperature of \>38.3 degree Celsius (C) or a sustained temperature of \>=38 degree C for more than one hour; grade \>=3 neutropenia with infection; grade 4 thrombocytopenia; grade 3 thrombocytopenia with \>= Grade 2 bleeding. Non-hematological: grade 4 adverse events (AEs); Grade 3 AE lasting \>=5 days despite optimal supportive care, with exception of AE attributed to cytokine release syndrome (CRS) event; grade 3 CRS, except those CRS that had a) not been maximally treated or b) improved to \<=grade 1 within 48 hours; grade 4 CRS; confirmed drug-induced liver injury (DILI) meeting Hy's law criteria; grade 4 laboratory abnormalities deemed clinically significant by the investigator reported Grade 4 AE; clinically important or persistent toxicities that were not included in above criteria were also be considered a DLT following review by the investigators and the sponsor.
| Participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v)4.03 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 0 | 1 |
ORR per IMWG criteria: percentage of participants with best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). sCR: complete response plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein and reduction in 24 hrs urinary M-protein by \>=90% or to \<200 mg/24 hr. If serum and urine M-protein were unmeasurable, \>=50% decrease in difference between involved and uninvolved FLC levels required in place of the M-protein criteria.
| Percentage of participants | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria | 60.0 (35.7 to 80.2) |
DOR per IMWG criteria:time from first documentation of objective tumor (OT)response to first documentation of OTprogression or to death due to any cause, whichever occurred first.sCR: CR plus normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry;CR:Negative immunofixation on serum \& urine \& disappearance of any soft tissue plasmacytomas\&\<5% plasma cells in bone marrow aspirates.VGPR: serum \& urine M-protein(Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hrs urinary Mp by \>=90% or to \<200 mg/24 hr.If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It did not include second primary malignancies of unrelated types.
| Months | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: Duration of Response (DOR) as Per IMWG Criteria | 11.6 (2.5 to NA) |
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to intervention. TEAE: any event increasing in severity from baseline or event started during PF-06863135 therapy or within 30 days of last dose of drug. SAE: any untoward medical occurrence at any dose that resulted in either: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via Pfizer product of infectious agent, pathogenic or non-pathogenic; or considered as important event. Treatment-related AE: AEs attributed to drug in participants who received drug. Relatedness was judged by investigator. NCI CTCAE v4.03, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. AEs included SAEs and all non-SAEs.
| Participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | 2 | 3 | 2 | 3 | 2 | 5 | 6 | 6 | 4 | 4 | 4 | 6 | 6 | 7 | 13 | 4 | 9 | 23 | 30 | 20 |
| Participants with serious TEAEs | 0 | 1 | 0 | 3 | 0 | 2 | 5 | 4 | 1 | 3 | 3 | 4 | 5 | 6 | 9 | 2 | 8 | 11 | 20 | 15 |
| Participants with treatment related AEs | 2 | 1 | 1 | 1 | 2 | 4 | 6 | 4 | 4 | 4 | 4 | 6 | 6 | 7 | 13 | 4 | 9 | 17 | 28 | 20 |
| Participants with grade 3 or 4 AEs | 1 | 2 | 1 | 2 | 2 | 3 | 6 | 3 | 4 | 3 | 4 | 4 | 6 | 3 | 12 | 4 | 7 | 17 | 24 | 15 |
| Participants with grade 5 AEs | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | 0 | 1 | 0 | 2 | 0 | 3 | 1 | 0 | 2 | 2 | 6 | 4 |
Hematology parameters included: activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and, white blood cell decreased. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of hematology parameters are reported.
| Participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Shifts From Grade Less Than or Equal to (<=) 2 at Baseline to Grade 3 or 4 Post-Baseline in Hematology Parameters | 1 | 2 | 2 | 2 | 2 | 5 | 5 | 6 | 3 | 4 | 4 | 6 | 6 | 6 | 13 | 4 | 9 | 19 | 29 | 19 |
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of clinical chemistry parameters are reported.
| Participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Shifts From Grade <= 2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Chemistry Parameters | 0 | 2 | 0 | 1 | 0 | 2 | 1 | 2 | 0 | 2 | 2 | 3 | 2 | 3 | 8 | 4 | 3 | 6 | 11 | 11 |
Proteinuria was estimated in urinalysis. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of urinalysis parameters are reported.
| Participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Shifts From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Urinalysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORR per IMWG criteria: percentage of participants with best overall response (BOR) of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). sCR: complete response plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein and reduction in 24 hrs urinary M-protein by \>=90% or to \<200 mg/24 hr. If serum and urine M-protein were unmeasurable, \>=50% decrease in difference between involved and uninvolved FLC levels required in place of the M-protein criteria.
| Percentage of participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: ORR as Per IMWG Criteria | 0 (0.0 to 65.8) | 0 (0.0 to 56.1) | 0 (0.0 to 65.8) | 0 (0.0 to 56.1) | 0 (0.0 to 65.8) | 0 (0.0 to 43.4) | 0 (0.0 to 39.0) | 0 (0.0 to 39.0) | 0 (0.0 to 49.0) | 50.0 (15.0 to 85.0) | 75.0 (30.1 to 95.4) | 66.7 (30.0 to 90.3) | 83.3 (43.6 to 97.0) | 57.1 (25.0 to 84.2) | 61.5 (25.5 to 82.3) | 75.0 (30.1 to 95.4) | 77.8 (45.3 to 93.7) | 0 (0.0 to 14.3) | 46.7 (30.2 to 63.9) | 60.0 (38.7 to 78.1) |
TTR: Defined for participants with confirmed objective response as time from first dose to first documentation of objective tumor response. sCR: complete response + normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum\& urine \& disappearance of soft tissue plasmacytomas \& \<5% plasma cells in bone marrow aspirates. VGPR: serum\& urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein\& reduction in 24hrs urinary M-protein by \>=90% or \<200 mg/24hr. If serum \& urine M-protein unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of M-protein criteria. Progression: Appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
| Days | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Time to Response (TTR) as Per IMWG Criteria | — | — | — | — | — | — | — | — | — | 22.0 (22 to 22) | 22.0 (22 to 24) | 22.0 (21 to 23) | 42.0 (22 to 92) | 39.0 (8 to 65) | 36.0 (7 to 73) | 52.0 (8 to 281) | 50.0 (7 to 105) | — | 22.0 (21 to 92) | 36.0 (7 to 73) |
CRR: percentage of participants with complete response (sCR or CR). sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
| Percentage of participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Complete Response Rate (CRR) as Per IMWG Criteria | 0 (0.0 to 65.8) | 0 (0.0 to 56.1) | 0 (0.0 to 65.8) | 0 (0.0 to 56.1) | 0 (0.0 to 65.8) | 0 (0.0 to 43.4) | 0 (0.0 to 39.0) | 0 (0.0 to 39.0) | 0 (0.0 to 49.0) | 50.0 (15.0 to 85.0) | 25.0 (4.6 to 69.9) | 50.0 (18.8 to 81.2) | 50.0 (18.8 to 81.2) | 14.3 (2.6 to 51.3) | 46.2 (23.2 to 70.9) | 50.0 (15.0 to 85.0) | 33.3 (12.1 to 64.6) | 0 (0.0 to 14.3) | 30.0 (16.7 to 47.9) | 35.0 (18.1 to 56.7) |
DOR per IMWG criteria:time from first documentation of objective tumor (OT)response to first documentation of OTprogression or to death due to any cause, whichever occurred first.sCR: CR plus normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry;CR:Negative immunofixation on serum \& urine \& disappearance of any soft tissue plasmacytomas\&\<5% plasma cells in bone marrow aspirates.VGPR: serum \& urine M-protein(Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hrs urinary Mp by \>=90% or to \<200 mg/24 hr.If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It did not include second primary malignancies of unrelated types.
| Months | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: DOR as Per IMWG Criteria | — | — | — | — | — | — | — | — | — | 25.3 (18.4 to NA) | 13.6 (5.4 to NA) | NA (32.2 to NA) | NA (6.3 to NA) | 6.7 (3.7 to NA) | 17.1 (10.6 to NA) | 14.9 (11.8 to NA) | 8.3 (2.9 to NA) | — | 32.2 (7.0 to NA) | 13.3 (6.3 to NA) |
DoCR was defined for participants with confirmed complete response (sCR or CR) as the time from the first documentation of complete response to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. Progression was defined as appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
| Months | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Duration of Complete Response (DoCR) as Per IMWG Criteria | — | — | — | — | — | — | — | — | — | 25.3 (18.4 to NA) | NA (NA to NA) | NA (NA to NA) | NA (7.0 to NA) | NA (NA to NA) | NA (6.5 to NA) | NA (10.3 to NA) | NA (3.7 to NA) | — | 31.5 (7.0 to NA) | 11.5 (1.9 to NA) |
DOSD per IMWG criteria: participants with confirmed stable disease (SD): time from first documentation (doc) of objective SD to first doc of objective tumor progression (P)/death by any cause, whichever occurred first. SD: not meeting criteria for CR,VGPR, PR, MR or PD. CR: Negative immunofixation on serum \& urine \&disappearance of any soft tissue plasmacytomas \&\<5% plasma cells in bone marrow aspirates. VGPR: serum \& urine M-protein (Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hours urinary Mp by \>=90% or\<200 mg/24 hr. If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
| Months | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Duration of Stable Disease (DOSD) as Per IMWG Criteria | — | 1.3 (0.5 to NA) | NA (NA to NA) | 0.8 (0.6 to NA) | NA (NA to NA) | 3.4 (1.0 to NA) | 3.0 (2.2 to NA) | 0.4 (0.3 to NA) | 0.6 (0.5 to NA) | 18.4 (4.2 to NA) | 13.6 (5.4 to NA) | 32.2 (2.1 to NA) | NA (7.0 to NA) | 7.4 (3.7 to NA) | 17.6 (11.5 to NA) | 17.9 (1.5 to NA) | 5.6 (0.7 to NA) | 1.8 (0.6 to 3.4) | 7.3 (1.4 to 32.3) | 12.0 (7.4 to 20.2) |
PFS as per IMWG criteria was the time from start date of study treatment to date of first documentation of progression, or death due to any cause. Progression was defined as the appearance of local, regional or distant disease of the same type after CR or progression of pre-existing lesions. It does not include second primary malignancies of unrelated types. CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
| Months | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Progression Free Survival (PFS) as Per IMWG Criteria | 0.4 (0.3 to NA) | 0.7 (0.3 to NA) | 1.1 (0.7 to NA) | 1.7 (0.6 to NA) | 1.6 (0.6 to NA) | 1.6 (0.6 to NA) | 2.9 (0.8 to NA) | 1.0 (0.7 to NA) | 1.0 (0.7 to NA) | 19.1 (4.8 to NA) | 10.2 (0.7 to NA) | 32.9 (0.7 to NA) | 8.0 (0.7 to NA) | 7.6 (3.9 to NA) | 12.7 (0.5 to NA) | 18.1 (1.7 to NA) | 6.7 (0.9 to NA) | 1.4 (0.6 to 2.6) | 4.8 (1.1 to 14.4) | 12.2 (3.9 to 19.2) |
OS was defined as the time from start date of study treatment to date of death due to any cause. OS for participants not known to had died were censored on the date of last known alive.
| Months | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Overall Survival (OS) | 8.2 (4.4 to NA) | 8.4 (1.9 to NA) | 11.2 (4.4 to NA) | 8.1 (1.7 to NA) | 16.2 (9.4 to NA) | 14.8 (2.4 to NA) | 18.0 (5.0 to NA) | 1.7 (0.8 to NA) | NA (3.8 to NA) | 19.1 (8.8 to NA) | 14.0 (3.0 to NA) | 32.9 (12.0 to NA) | NA (2.2 to NA) | 8.3 (3.9 to NA) | NA (1.1 to NA) | 31.3 (28.3 to NA) | NA (5.7 to NA) | 12.0 (7.9 to 17.1) | 17.3 (6.2 to 44.8) | NA (5.4 to NA) |
MRD negativity rate: percentage of participants with negative MRD (assessed by central laboratory) per IMWG criteria at any time from date of first dose until first documentation of confirmed progression, death or start of new anticancer therapy, whichever occurred first. Progression was defined as appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types. MRD negativity was defined by two thresholds, 10\^-5 and 10\^-6.
| Percentage of participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10^-5 threshold MRD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50.00 | 0 | 16.67 | 16.67 | 28.57 | 38.46 | 25.00 | 0 | 0 | 13.33 | 35.00 |
| 10^-6 threshold MRD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.00 | 0 | 16.67 | 16.67 | 0 | 30.77 | 0 | 0 | 0 | 10.00 | 20.00 |
Cmax of PF-06863135 was measured in this outcome measure. Total is free and bound drug in the body.
| Micrograms per milliliter | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total PF-06863135: Cycle 0 Day 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.639 ± 21 | 4.216 ± 42 | 2.144 ± 96 | 2.277 ± 51 |
| Total PF-06863135: Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | 0.05363 ± 36 | NA ± NA | 0.6044 ± 27 | 0.8725 ± 41 | 0.2866 ± 46 | 0.9076 ± 24 | 1.220 ± 25 | 2.568 ± 42 | 3.802 ± 12 | 3.620 ± 53 | 9.927 ± 18 | 8.710 ± 54 | 5.513 ± 141 | 5.814 ± 36 |
| Total PF-06863135: Cycle 2 Day 1 | — | NA ± NA | NA | NA ± NA | NA | 0.9924 ± 8 | 1.684 ± 23 | 0.6904 ± 55 | 2.108 ± 38 | 3.021 ± 24 | 5.748 ± 16 | 11.92 ± 28 | 12.98 ± 26 | 25.74 ± 19 | 12.03 ± 67 | NA | NA ± NA |
| Free PF-06863135: Cycle 0 Day 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.9445 ± 59 | 1.087 ± 79 | 0.5165 ± 83 | 0.8080 ± 59 |
| Free PF-06863135: Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | 0.0008828 ± 1.23 | NA ± NA | 0.1851 ± 40 | 0.3015 ± 75 | 0.09913 ± 36 | 0.2479 ± 28 | 0.5916 ± 47 | 0.8304 ± 131 | 0.9875 ± 52 | 0.8266 ± 66 | 2.088 ± 106 | 2.485 ± 91 | 1.185 ± 90 | 2.150 ± 76 |
| Free PF-06863135: Cycle 2 Day 1 | — | NA ± NA | NA | NA ± NA | NA ± NA | 0.2855 ± 37 | 0.2955 ± 4 | 0.1794 ± 40 | 0.3998 ± 41 | 1.473 ± 79 | 1.605 ± 182 | 7.981 ± 79 | 3.953 ± 156 | 11.00 ± 186 | 5.323 ± 69 | NA | NA ± NA |
Area under the concentration curve from time 0 to end of dosing interval (AUCtau) was measured in this outcome measure. Total is free and bound drug in the body.
| Microgram*day per milliliter | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total PF-06863135: Cycle 0 Day 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | 16.82 ± 20 | 16.93 ± 46 | 9.643 ± 148 | 10.91 ± 37 |
| Total PF-06863135: Cycle 1 Day 1 | NA | NA ± NA | NA ± NA | 0.1654 ± 74 | NA ± NA | 2.190 ± 11 | 3.322 ± 40 | 1.182 ± 58 | 4.426 ± 17 | NA ± NA | 12.58 ± 26 | 17.92 ± 29 | 25.53 ± 36 | 58.93 ± 14 | 93.96 ± 53 | 54.78 ± 16 | 31.92 ± 45 |
| Total PF-06863135: Cycle 2 Day 1 | — | NA | NA | — | — | NA ± NA | NA ± NA | NA ± NA | 13.47 ± 39 | — | NA ± NA | 76.83 ± 30 | 88.92 ± 31 | 173.4 ± 21 | 148.1 ± 65 | — | NA ± NA |
| Free PF-06863135: Cycle 0 Day 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.111 ± 49 | 5.054 ± 73 | 2.447 ± 92 | 3.487 ± 50 |
| Free PF-06863135: Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | 0.0009462 ± 1.95 | NA ± NA | 0.7801 ± 24 | 1.206 ± 62 | 0.3344 ± 72 | 1.478 ± 23 | NA ± NA | 4.362 ± 103 | 4.909 ± 42 | 6.564 ± 33 | 11.92 ± 109 | 34.13 ± 60 | 8.896 ± 12 | 11.40 ± 91 |
| Free PF-06863135: Cycle 2 Day 1 | — | NA ± NA | NA | NA ± NA | NA | 0.05280 ± 2.59 | NA ± NA | NA ± NA | 2.572 ± 49 | — | NA ± NA | 45.14 ± 113 | 34.18 ± 155 | 45.63 ± 128 | 66.20 ± 63 | — | NA ± NA |
Plasma concentration of lenalidomide and pomalidomide was measured in this outcome measure.
| nanogram/milliliter | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC |
|---|---|---|
| Cycle 1 Day 1 | NA (NA to NA) | NA (NA to NA) |
| Cycle 1 Day 8 | 70.70 (70.7 to 70.7) | 13.60 (0.000 to 57.8) |
| Cycle 1 Day 15 | 70.60 (70.6 to 70.6) | 32.70 (0.000 to 49.1) |
| Cycle 2 Day 15 | 36.70 (20.2 to 234) | 0.0000 (0.000 to 7.41) |
Number of participants with ADA and NAb against PF-06863135 were reported in this outcome measure. A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-folder dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
| Participants | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADA positive | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| NAb positive | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The concentration of Interleukin-2, Interleukin-6, Interferon-gamma and tumor necrosis factor-alpha were measured in this outcome measure. Cycle = C.
| Picogram per milliliter | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interleukin-2: Cycle 0; 0 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 0; 2 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.10 (2.1 to 9.1) | 2.10 (2.1 to 55.0) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 10.5) |
| Interleukin-2: Cycle 0; 4 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.70 (2.1 to 19.7) | 3.60 (2.1 to 247.4) | 2.10 (2.1 to 6.5) | 2.40 (2.1 to 20.9) |
| Interleukin-2: Cycle 0; 8 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 14.30 (2.1 to 487.8) | 17.90 (2.1 to 118.1) | 2.10 (2.1 to 82.0) | 2.10 (2.1 to 1063.8) |
| Interleukin-2: Cycle 0; 24 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.10 (2.1 to 12.2) | 2.10 (2.1 to 15.5) | 2.10 (2.1 to 2.3) | 2.10 (2.1 to 7.1) |
| Interleukin-2: Cycle 1; 0 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 24.0) | 5.00 (5.0 to 37.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (2.1 to 5.0) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 2 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 12.50 (5.0 to 112.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (2.1 to 5.0) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 4 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.50 (5.0 to 6.0) | 53.00 (5.0 to 80.0) | 83.00 (21.0 to 202.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 12.0) | 5.00 (5.0 to 5.0) | 5.50 (5.0 to 7.0) | 5.00 (2.1 to 6.7) | 2.10 (2.1 to 34.9) | 2.10 (2.1 to 2.2) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 8 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 11.0 (5.0 to 43.0) | 5.00 (5.0 to 52.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 50.0) | 8.50 (5.0 to 15.0) | 12.50 (5.0 to 39.0) | 5.00 (2.1 to 20.0) | 2.10 (2.1 to 55.7) | 2.10 (2.1 to 18.3) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.4) | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 24 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 9.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (2.1 to 5.0) | 2.10 (2.1 to 5.8) | 2.10 (2.1 to 2.7) | 2.10 (2.1 to 8.0) | 2.10 (2.1 to 7.4) | 2.10 (2.1 to 7.2) |
| Interleukin-2: Cycle 1; 72 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 14.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (2.1 to 5.0) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 2.1) | 2.10 (2.1 to 4.7) | 2.10 (2.1 to 3.5) |
| Interleukin-6: Cycle 0; 0 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.00 (2.0 to 4.9) | 2.00 (2.0 to 17.4) | 2.00 (2.0 to 2.9) | 2.00 (2.0 to 2.5) |
| Interleukin-6: Cycle 0; 2 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.10 (2.0 to 10.8) | 2.00 (2.0 to 60.5) | 2.00 (2.0 to 3.6) | 2.00 (2.0 to 2.2) |
| Interleukin-6: Cycle 0; 4 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 11.50 (3.2 to 63.6) | 10.40 (2.0 to 843.7) | 3.75 (2.0 to 17.1) | 5.25 (2.0 to 88.5) |
| Interleukin-6: Cycle 0; 8 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 88.40 (14.8 to 1821.1) | 129.90 (2.0 to 1028.0) | 3.70 (2.2 to 670.4) | 2.00 (2.0 to 169.8) |
| Interleukin-6: Cycle 0; 24 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 201.40 (15.1 to 428.4) | 122.70 (2.6 to 2396.8) | 8.50 (5.3 to 1651.0) | 33.60 (4.7 to 882.2) |
| Interleukin-6: Cycle 1; 0 hours | 7.00 (5.0 to 9.0) | 5.00 (5.0 to 5.0) | 6.50 (5.0 to 8.0) | 5.00 (5.0 to 12.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 32.0) | 5.00 (5.0 to 7.0) | 5.00 (5.0 to 32.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 6.50 (5.0 to 23.0) | 5.00 (2.0 to 5.0) | 2.00 (2.0 to 28.1) | 59.20 (9.6 to 370.9) | 24.50 (2.1 to 212.3) | 9.30 (2.0 to 219.5) | 2.00 (2.0 to 146.8) |
| Interleukin-6: Cycle 1; 2 hours | 6.00 (5.0 to 7.0) | 5.00 (5.0 to 5.0) | 17.00 (5.0 to 29.0) | 5.00 (5.0 to 14.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 29.0) | 9.50 (5.0 to 56.0) | 5.00 (5.0 to 43.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 6.50 (5.0 to 20.0) | 5.00 (2.0 to 5.0) | 2.00 (2.0 to 151.6) | 56.45 (7.7 to 205.1) | 20.60 (2.7 to 150.5) | 8.05 (2.0 to 278.8) | 2.30 (2.0 to 200.5) |
| Interleukin-6: Cycle 1; 4 hours | 6.50 (5.0 to 8.0) | 5.00 (5.0 to 5.0) | 7.00 (5.0 to 9.0) | 5.00 (5.0 to 16.0) | 5.00 (5.0 to 5.0) | 106.00 (5.0 to 206.0) | 73.00 (15.0 to 813.0) | 5.00 (5.0 to 54.0) | 5.00 (5.0 to 12.0) | 5.00 (5.0 to 7.0) | 15.50 (5.0 to 71.0) | 5.00 (3.5 to 21.7) | 8.95 (2.0 to 20.0) | 58.70 (5.5 to 303.8) | 22.95 (3.2 to 187.4) | 7.45 (2.0 to 292.6) | 2.25 (2.0 to 165.0) |
| Interleukin-6: Cycle 1; 8 hours | 5.50 (5.0 to 6.0) | 5.00 (5.0 to 5.0) | 6.50 (5.0 to 8.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 40.00 (5.0 to 327.0) | 25.00 (5.0 to 263.0) | 5.00 (5.00 to 33.0) | 8.00 (5.0 to 54.0) | 46.50 (5.0 to 67.0) | 184.50 (12.0 to 342.0) | 12.00 (5.0 to 33.6) | 24.85 (2.0 to 2080.9) | 52.50 (6.9 to 125.1) | 35.00 (5.1 to 174.8) | 12.80 (2.0 to 634.1) | 2.00 (2.0 to 621.5) |
| Interleukin-6: Cycle 1; 24 hours | 7.00 (5.0 to 9.0) | 5.00 (5.0 to 5.0) | 8.00 (5.0 to 11.0) | 5.00 (5.0 to 163.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 45.0) | 6.00 (5.0 to 18.0) | 7.00 (5.0 to 64.0) | 9.00 (5.0 to 13.0) | 16.50 (6.0 to 51.0) | 29.00 (13.0 to 209.0) | 21.50 (5.0 to 976.8) | 31.25 (2.3 to 250.0) | 129.65 (10.5 to 631.3) | 38.35 (3.5 to 250.3) | 12.15 (2.0 to 577.6) | 2.90 (2.0 to 78.7) |
| Interleukin-6: Cycle 1; 72 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 8.50 (5.0 to 12.0) | 5.00 (5.0 to 56.0) | 5.00 (5.0 to 5.0) | 7.00 (5.0 to 37.0) | 5.00 (5.0 to 11.0) | 10.00 (5.0 to 13.0) | 6.00 (5.0 to 9.0) | 10.50 (5.0 to 74.0) | 11.0 (5.0 to 946.0) | 18.50 (5.0 to 224.2) | 7.20 (2.0 to 45.1) | 89.20 (11.1 to 161.3) | 30.45 (2.0 to 170.4) | 12.25 (2.0 to 188.3) | 32.75 (2.0 to 1239.3) |
| Interferon-gamma: Cycle 0; 0 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 0; 2 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 0; 4 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.20 (4.2 to 13.8) | 4.20 (2.2 to 18.3) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 12.8) |
| Interferon-gamma: Cycle 0; 8 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 10.30 (4.2 to 487.8) | 7.20 (4.2 to 34.6) | 4.20 (4.2 to 26.3) | 4.20 (4.2 to 106.1) |
| Interferon-gamma: Cycle 0; 24 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.00 (4.2 to 28.4) | 7.40 (4.2 to 17.4) | 4.20 (4.2 to 25.6) | 4.20 (4.2 to 23.1) |
| Interferon-gamma: Cycle 1; 0 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 7.0) | 5.00 (5.0 to 164.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (4.2 to 5.0) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 5.9) |
| Interferon-gamma: Cycle 1; 2 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (4.2 to 5.0) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.9) | 4.20 (4.2 to 7.3) |
| Interferon-gamma: Cycle 1; 4 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 9.00 (5.0 to 13.0) | 10.00 (5.0 to 33.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (4.2 to 5.0) | 4.20 (4.2 to 19.0) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 5.2) |
| Interferon-gamma: Cycle 1; 8 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 8.50 (5.0 to 39.0) | 5.00 (5.0 to 16.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.50 (5.0 to 8.0) | 5.50 (5.0 to 22.0) | 5.00 (4.2 to 6.0) | 4.20 (4.2 to 56.9) | 4.20 (4.2 to 5.5) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 7.0) |
| Interferon-gamma: Cycle 1; 24 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 9.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 7.00 (5.0 to 12.0) | 5.00 (5.0 to 20.0) | 5.00 (5.0 to 12.1) | 4.20 (4.2 to 5.9) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 20.4) |
| Interferon-gamma: Cycle 1; 72 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (4.2 to 5.0) | 4.20 (0.4 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 4.2) | 4.20 (4.2 to 8.4) |
| Tumor necrosis factor-alpha: Cycle 0; 0 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.70 (1.7 to 1.7) | 1.70 (1.7 to 17.7) | 2.00 (1.7 to 2.3) | 1.70 (1.7 to 1.7) |
| Tumor necrosis factor-alpha: Cycle 0; 2 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.70 (1.7 to 2.8) | 1.70 (1.7 to 75.6) | 1.70 (1.7 to 3.5) | 2.35 (1.7 to 6.2) |
| Tumor necrosis factor-alpha: Cycle 0; 4 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.30 (1.7 to 27.7) | 2.50 (1.7 to 164.2) | 2.60 (1.7 to 9.7) | 1.70 (1.7 to 8.9) |
| Tumor necrosis factor-alpha: Cycle 0; 8 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 9.70 (1.7 to 46.2) | 7.40 (1.7 to 39.2) | 3.05 (1.7 to 39.1) | 1.75 (1.7 to 114.2) |
| Tumor necrosis factor-alpha: Cycle 0; 24 hours | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.80 (1.7 to 9.1) | 3.80 (1.7 to 15.1) | 3.15 (1.7 to 4.2) | 2.30 (1.7 to 8.5) |
| Tumor necrosis factor-alpha: Cycle 1; 0 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 41.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 25.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 37.0) | 5.00 (1.7 to 16.0) | 1.70 (1.7 to 18.4) | 1.70 (1.7 to 2.2) | 1.70 (1.7 to 10.3) | 3.15 (1.7 to 4.6) | 1.70 (1.7 to 3.3) |
| Tumor necrosis factor-alpha: Cycle 1; 2 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 8.0) | 8.50 (5.0 to 21.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (1.7 to 15.0) | 1.70 (1.7 to 25.5) | 1.70 (1.7 to 1.7) | 1.80 (1.7 to 14.7) | 2.55 (1.7 to 4.1) | 1.70 (1.7 to 6.5) |
| Tumor necrosis factor-alpha: Cycle 1; 4 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 11.0 (5.0 to 70.0) | 8.00 (5.0 to 138.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (1.7 to 12.0) | 1.70 (1.7 to 147.3) | 1.70 (1.7 to 2.7) | 1.70 (1.7 to 6.3) | 2.80 (1.7 to 4.0) | 1.70 (1.7 to 4.0) |
| Tumor necrosis factor-alpha: Cycle 1; 8 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 6.0) | 5.00 (5.0 to 12.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 6.0) | 6.50 (5.0 to 35.0) | 8.00 (5.0 to 11.0) | 5.00 (1.7 to 27.0) | 1.70 (1.7 to 458.0) | 1.70 (1.7 to 1.9) | 1.70 (1.7 to 11.6) | 1.70 (1.7 to 5.3) | 1.70 (1.4 to 5.8) |
| Tumor necrosis factor-alpha: Cycle 1; 24 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 7.0) | 5.00 (5.0 to 12.0) | 5.00 (1.7 to 9.0) | 1.70 (1.7 to 2.0) | 1.70 (1.7 to 2.1) | 2.45 (1.7 to 8.0) | 2.90 (1.7 to 4.1) | 1.70 (1.7 to 6.2) |
| Tumor necrosis factor-alpha: Cycle 1; 72 hours | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 15.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 5.0) | 5.00 (5.0 to 10.0) | 5.00 (5.0 to 5.0) | 5.00 (1.7 to 5.0) | 1.70 (1.7 to 3.4) | 1.70 (1.7 to 4.2) | 1.70 (1.7 to 6.7) | 3.85 (1.7 to 6.9) | 1.70 (1.7 to 3.6) |
AE: any untoward medical occurrence in clinical study participant, temporally associated with use of study intervention, whether or not considered related to intervention. TEAE: any event increasing in severity from baseline or event started during PF-06863135 therapy or within 30 days of last dose of drug. SAE: any untoward medical occurrence at any dose that resulted in either: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via Pfizer product of infectious agent, pathogenic or non-pathogenic; or considered as important event. Treatment-related AE: AEs attributed to drug in participants who received drug. Relatedness was judged by investigator. NCI CTCAE v4.03, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. AEs included SAEs and all non-SAEs.
| Participants | Part 2A: PF-06863135 SC |
|---|---|
| Participants with TEAEs | 15 |
| Participants with serious AEs | 12 |
| Participants with treatment related AEs | 13 |
| Participants with grade 3 or 4 AEs | 11 |
| Participants with grade 5 AEs | 3 |
Hematology parameters included: activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and, white blood cell decreased. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of hematology parameters are reported.
| Participants | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: Number of Participants With Shifts From Grade <=2 at Baseline to Grade 3 or 4 Post-Baseline in Hematology Parameters | 15 |
Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of clinical chemistry parameters are reported.
| Participants | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: Number of Participants With Shifts From Grade <= 2 at Baseline to Grade 3 or 4 Post-Baseline in Clinical Chemistry Parameters | 8 |
Proteinuria was estimated in urinalysis. According to NCI CTCAE version 4.03: Grade 1= mild, Gade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE. In this outcome measure number of participants with shifts from grade 2 at baseline to grade 3 or 4 post-baseline in any of urinalysis parameters are reported.
| Participants | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: Number of Participants With Shifts From Grade <=2 to Grade 3 or 4 Post-Baseline in Urinalysis | 0 |
CRR: percentage of participants with complete response (sCR or CR). sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
| Percentage of participants | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: CRR as Per IMWG Criteria | 33.3 (15.2 to 58.3) |
DoCR was defined for participants with confirmed complete response (sCR or CR) as the time from the first documentation of complete response to the first documentation of objective tumor progression or to death due to any cause, whichever occured first. sCR: complete response plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates. Progression was defined as appearance of local, regional or distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
| Months | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: DoCR as Per IMWG Criteria | 9.4 (6.5 to NA) |
TTR: Defined for participants with confirmed objective response as time from first dose to first documentation of objective tumor response. sCR: complete response + normal FLC ratio \& absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR: Negative immunofixation on serum\& urine \& disappearance of soft tissue plasmacytomas \& \<5% plasma cells in bone marrow aspirates. VGPR: serum\& urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24 hr. PR: \>=50% reduction of serum M-protein\& reduction in 24hrs urinary M-protein by \>=90% or \<200 mg/24hr. If serum \& urine M-protein unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of M-protein criteria. Progression: Appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
| Days | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: TTR as Per IMWG Criteria | 40.0 (8 to 262) |
DOSD per IMWG criteria: participants with confirmed stable disease (SD): time from first documentation (doc) of objective SD to first doc of objective tumor progression (P)/death by any cause, whichever occurred first. SD: not meeting criteria for CR,VGPR, PR, MR or PD. CR: Negative immunofixation on serum \& urine \&disappearance of any soft tissue plasmacytomas \&\<5% plasma cells in bone marrow aspirates. VGPR: serum \& urine M-protein (Mp) detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum Mp plus urine Mp level \<100 mg/24 hr. PR: \>=50% reduction of serum Mp \& reduction in 24 hours urinary Mp by \>=90% or\<200 mg/24 hr. If serum \& urine Mp were unmeasurable, \>=50% decrease in difference between involved \& uninvolved FLC levels required in place of Mp criteria. Progression: appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types.
| Months | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: DOSD as Per IMWG Criteria | 11.6 (1.9 to NA) |
PFS as per IMWG criteria was the time from start date of study treatment to date of first documentation of progression, or death due to any cause. Progression was defined as the appearance of local, regional or distant disease of the same type after CR or progression of pre-existing lesions. It does not include second primary malignancies of unrelated types. CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow aspirates.
| Months | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: PFS as Per IMWG Criteria | 10.4 (1.2 to 20.0) |
OS was defined as the time from start date of study treatment to date of death due to any cause. OS for participants not known to had died were censored on the date of last known alive.
| Months | Part 2A: PF-06863135 SC |
|---|---|
| Part 2: OS | 12.1 (4.2 to NA) |
MRD negativity rate: percentage of participants with negative MRD (assessed by central laboratory) per IMWG criteria at any time from date of first dose until first documentation of confirmed progression, death or start of new anticancer therapy, whichever occurred first. Progression was defined as appearance of local, regional, distant disease of same type after CR or progression of pre-existing lesions. It didn't include second primary malignancies of unrelated types. MRD negativity was defined by two thresholds, 10\^-5 and 10\^-6.
| Percentage of Participants | Part 2A: PF-06863135 SC |
|---|---|
| 10^-5 threshold MRD | 33.33 |
| 10^-6 threshold MRD | 13.33 |
Number of participants with ADA and NAb against PF-06863135 were reported in this outcome measure. A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= 4-folder dilution increase in titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
| Participants | Part 2A: PF-06863135 SC |
|---|---|
| ADA positive | 0 |
| NAb positive | 0 |
The concentration of Interleukin-2, Interleukin-6, Interferon-gamma and tumor necrosis factor-alpha were measured in this outcome measure.
| Picogram per milliliter | Part 2A: PF-06863135 SC |
|---|---|
| Interleukin-2: Cycle 0; 0 hours | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 0; 2 hours | 2.10 (2.1 to 27.5) |
| Interleukin-2: Cycle 0; 4 hours | 2.10 (2.1 to 48.6) |
| Interleukin-2: Cycle 0; 8 hours | 2.10 (2.1 to 10.6) |
| Interleukin-2: Cycle 0; 24 hours | 2.10 (2.1 to 30.1) |
| Interleukin-2: Cycle 1; 0 hours | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 2 hours | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 4 hours | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 8 hours | 2.10 (2.1 to 3.0) |
| Interleukin-2: Cycle 1; 24 hours | 2.10 (2.1 to 2.1) |
| Interleukin-2: Cycle 1; 72 hours | 2.10 (2.1 to 2.1) |
| Interleukin-6: Cycle 0; 0 hours | 2.00 (2.0 to 63.1) |
| Interleukin-6: Cycle 0; 2 hours | 2.00 (2.0 to 7.0) |
| Interleukin-6: Cycle 0; 4 hours | 2.00 (2.0 to 23.1) |
| Interleukin-6: Cycle 0; 8 hours | 2.00 (2.0 to 9.3) |
| Interleukin-6: Cycle 0; 24 hours | 10.30 (2.0 to 2480.3) |
| Interleukin-6: Cycle 1; 0 hours | 5.05 (2.0 to 156.0) |
| Interleukin-6: Cycle 1; 2 hours | 2.00 (2.0 to 88.6) |
| Interleukin-6: Cycle 1; 4 hours | 2.30 (2.0 to 78.9) |
| Interleukin-6: Cycle 1; 8 hours | 2.00 (2.0 to 53.3) |
| Interleukin-6: Cycle 1; 24 hours | 3.70 (2.0 to 466.7) |
| Interleukin-6: Cycle 1; 72 hours | 7.50 (2.0 to 1231.3) |
| Interferon-gamma: Cycle 0; 0 hours | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 0; 2 hours | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 0; 4 hours | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 0; 8 hours | 4.20 (3.0 to 4.2) |
| Interferon-gamma: Cycle 0; 24 hours | 4.20 (4.2 to 47.3) |
| Interferon-gamma: Cycle 1; 0 hours | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 1; 2 hours | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 1; 4 hours | 4.20 (2.2 to 4.2) |
| Interferon-gamma: Cycle 1; 8 hours | 4.20 (4.2 to 4.2) |
| Interferon-gamma: Cycle 1; 24 hours | 4.20 (4.2 to 7.5) |
| Interferon-gamma: Cycle 1; 72 hours | 4.20 (4.2 to 4.2) |
| Tumor necrosis factor-alpha: Cycle 0; 0 hours | 1.70 (1.7 to 2.8) |
| Tumor necrosis factor-alpha: Cycle 0; 2 hours | 1.70 (1.7 to 58.5) |
| Tumor necrosis factor-alpha: Cycle 0; 4 hours | 1.70 (1.7 to 20.8) |
| Tumor necrosis factor-alpha: Cycle 0; 8 hours | 1.70 (1.7 to 3.9) |
| Tumor necrosis factor-alpha: Cycle 0; 24 hours | 2.55 (1.7 to 12.7) |
| Tumor necrosis factor-alpha: Cycle 1; 0 hours | 1.70 (1.7 to 4.9) |
| Tumor necrosis factor-alpha: Cycle 1; 2 hours | 1.70 (1.7 to 5.2) |
| Tumor necrosis factor-alpha: Cycle 1; 4 hours | 1.70 (1.7 to 5.8) |
| Tumor necrosis factor-alpha: Cycle 1; 8 hours | 1.70 (1.7 to 3.6) |
| Tumor necrosis factor-alpha: Cycle 1; 24 hours | 1.70 (1.7 to 5.2) |
| Tumor necrosis factor-alpha: Cycle 1; 72 hours | 1.70 (1.7 to 2.9) |
Collected over Adverse events for Part 1: up to 43.3 months and for Part 2: up to 32.3 months; all-cause mortality for Part 1: 63.31 months and for Part 2: 34.3 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: PF-06863135 0.1 mcg/kg IV | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Part 1: PF-06863135 0.3 mcg/kg IV | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: PF-06863135 1 mcg/kg IV | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Part 1: PF-06863135 3 mcg/kg IV | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part 1: PF-06863135 10 mcg/kg IV | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Part 1: PF-06863135 30 mcg/kg IV | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Part 1: PF-06863135 50 mcg/kg IV | 4/6 (66.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Part 1: PF-06863135 80 mcg/kg SC | 5/6 (83.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Part 1: PF-06863135 130 mcg/kg SC | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Part 1: PF-06863135 215 mcg/kg SC | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Part 1: PF-06863135 360 mcg/kg SC | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Part 1: PF-06863135 600 mcg/kg SC | 3/6 (50%) | 4/6 (66.7%) | 6/6 (100%) |
| Part 1: PF-06863135 1000 mcg/kg SC | 2/6 (33.3%) | 5/6 (83.3%) | 6/6 (100%) |
| Part 1.1: PF-06863135 Priming Cohort Q1W SC | 3/7 (42.9%) | 6/7 (85.7%) | 7/7 (100%) |
| Part 1.1: PF-06863135 Priming Cohort Q2W SC | 4/13 (30.8%) | 9/13 (69.2%) | 13/13 (100%) |
| Part 1C: PF-06863135 + Lenalidomide SC | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Part 1D: PF-06863135 + Pomalidomide SC | 4/9 (44.4%) | 8/9 (88.9%) | 9/9 (100%) |
| Part 2A: PF-06863135 SC | 10/15 (66.7%) | 12/15 (80%) | 13/15 (86.7%) |
| Part 1: PF-06863135 Total IV | 19/23 (82.6%) | 11/23 (47.8%) | 23/23 (100%) |
| Part 1: PF-06863135 Total SC | 17/30 (56.7%) | 20/30 (66.7%) | 30/30 (100%) |
| Part 1.1: PF-06863135 Total SC | 7/20 (35%) | 15/20 (75%) | 20/20 (100%) |
| Event | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokine release syndromeImmune system disorders | 0/2 | 0/3 | 0/2 | 0/3 | 0/2 | 0/5 | 3/6 | 0/6 | 0/4 | 1/4 | 1/4 | 0/6 | 2/6 | 2/7 | 2/13 | 1/4 | 5/9 | 7/15 | 3/23 | 4/30 | 4/20 |
| AnaemiaBlood and lymphatic system disorders | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 1/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 1/30 | 0/20 |
| MelaenaGastrointestinal disorders | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 0/30 | 0/20 |
| Disease progressionGeneral disorders | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 1/5 | 0/6 | 2/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 1/13 | 0/4 | 0/9 | 2/15 | 2/23 | 2/30 | 1/20 |
| PyrexiaGeneral disorders | 0/2 | 0/3 | 0/2 | 0/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 2/6 | 1/6 | 0/7 | 1/13 | 0/4 | 1/9 | 1/15 | 0/23 | 3/30 | 1/20 |
| TracheobronchitisInfections and infestations | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 0/30 | 0/20 |
| Upper respiratory tract infectionInfections and infestations | 0/2 | 1/3 | 0/2 | 0/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 0/30 | 0/20 |
| FallInjury, poisoning and procedural complications | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 0/30 | 0/20 |
| Hip fractureInjury, poisoning and procedural complications | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 0/30 | 0/20 |
| Spinal cord compressionNervous system disorders | 0/2 | 0/3 | 0/2 | 1/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/6 | 0/7 | 0/13 | 0/4 | 0/9 | 0/15 | 1/23 | 0/30 | 0/20 |
| Event | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC | Part 1: PF-06863135 Total IV | Part 1: PF-06863135 Total SC | Part 1.1: PF-06863135 Total SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/2 | 2/3 | 1/2 | 1/3 | 2/2 | 4/5 | 3/6 | 4/6 | 3/4 | 3/4 | 4/4 | 3/6 | 5/6 | 6/7 | 9/13 | 1/4 | 3/9 | 6/15 | 14/23 | 22/30 | 15/20 |
| LymphopeniaBlood and lymphatic system disorders | 0/2 | 1/3 | 1/2 | 1/3 | 1/2 | 2/5 | 3/6 | 4/6 | 3/4 | 4/4 | 4/4 | 5/6 | 6/6 | 3/7 | 4/13 | 3/4 | 3/9 | 3/15 | 9/23 | 26/30 | 7/20 |
| Injection site reactionGeneral disorders | 0/2 | 0/3 | 0/2 | 0/3 | 0/2 | 0/5 | 0/6 | 0/6 | 3/4 | 2/4 | 1/4 | 5/6 | 5/6 | 6/7 | 6/13 | 4/4 | 6/9 | 6/15 | 0/23 | 16/30 | 12/20 |
| Cytokine release syndromeImmune system disorders | 0/2 | 0/3 | 0/2 | 0/3 | 1/2 | 4/5 | 5/6 | 2/6 | 2/4 | 2/4 | 2/4 | 6/6 | 4/6 | 6/7 | 11/13 | 1/4 | 3/9 | 3/15 | 10/23 | 18/30 | 17/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | 2/3 | 1/2 | 1/3 | 2/2 | 0/5 | 0/6 | 2/6 | 2/4 | 2/4 | 1/4 | 1/6 | 1/6 | 1/7 | 2/13 | 4/4 | 2/9 | 5/15 | 6/23 | 9/30 | 3/20 |
| Dry skinSkin and subcutaneous tissue disorders | 0/2 | 0/3 | 0/2 | 0/3 | 0/2 | 0/5 | 0/6 | 0/6 | 0/4 | 1/4 | 1/4 | 3/6 | 2/6 | 3/7 | 4/13 | 4/4 | 3/9 | 6/15 | 0/23 | 7/30 | 7/20 |
| NeutropeniaBlood and lymphatic system disorders | 1/2 | 1/3 | 0/2 | 1/3 | 0/2 | 2/5 | 2/6 | 0/6 | 2/4 | 3/4 | 1/4 | 5/6 | 5/6 | 6/7 | 11/13 | 3/4 | 7/9 | 10/15 | 7/23 | 16/30 | 17/20 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/2 | 1/3 | 1/2 | 2/3 | 1/2 | 0/5 | 4/6 | 5/6 | 2/4 | 3/4 | 1/4 | 4/6 | 2/6 | 3/7 | 10/13 | 1/4 | 3/9 | 5/15 | 10/23 | 17/30 | 13/20 |
| FatigueGeneral disorders | 0/2 | 0/3 | 1/2 | 1/3 | 0/2 | 4/5 | 1/6 | 1/6 | 1/4 | 0/4 | 1/4 | 2/6 | 2/6 | 3/7 | 8/13 | 1/4 | 7/9 | 7/15 | 7/23 | 7/30 | 11/20 |
| LeukopeniaBlood and lymphatic system disorders | 0/2 | 1/3 | 0/2 | 1/3 | 1/2 | 1/5 | 3/6 | 0/6 | 2/4 | 3/4 | 1/4 | 3/6 | 3/6 | 2/7 | 4/13 | 2/4 | 4/9 | 2/15 | 7/23 | 12/30 | 6/20 |
Safety analysis set included all participants who received at least 1 full or partial dose of study medication.
| Age, Continuous(Years) | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 58.0 ± 4.24 | 67.3 ± 4.04 | 53.0 ± 0.00 | 63.3 ± 9.24 | 54.5 ± 4.95 | 70.8 ± 14.15 | 67.0 ± 8.92 | 67.3 ± 8.73 | 63.8 ± 11.64 | 68.5 ± 9.11 | 62.0 ± 3.92 | 59.5 ± 8.31 | 58.5 ± 11.48 | 60.0 ± 12.22 | 67.4 ± 7.26 | 60.5 ± 22.49 | 58.9 ± 8.33 | 66.7 ± 9.65 | 63.7 ± 10.18 |
| Sex: Female, Male(Participants) | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 0 | 0 | 1 | 1 | 5 | 6 | 1 | 2 | 1 | 3 | 4 | 5 | 4 | 1 | 3 | 7 | 47 |
| Male | 0 | 2 | 2 | 3 | 1 | 4 | 1 | 0 | 3 | 2 | 3 | 3 | 2 | 2 | 9 | 3 | 6 | 8 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 4 |
| Not Hispanic or Latino | 2 | 3 | 1 | 3 | 2 | 5 | 6 | 6 | 4 | 4 | 4 | 6 | 5 | 7 | 13 | 4 | 8 | 13 | 96 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part 1: PF-06863135 0.1 mcg/kg IV | Part 1: PF-06863135 0.3 mcg/kg IV | Part 1: PF-06863135 1 mcg/kg IV | Part 1: PF-06863135 3 mcg/kg IV | Part 1: PF-06863135 10 mcg/kg IV | Part 1: PF-06863135 30 mcg/kg IV | Part 1: PF-06863135 50 mcg/kg IV | Part 1: PF-06863135 80 mcg/kg SC | Part 1: PF-06863135 130 mcg/kg SC | Part 1: PF-06863135 215 mcg/kg SC | Part 1: PF-06863135 360 mcg/kg SC | Part 1: PF-06863135 600 mcg/kg SC | Part 1: PF-06863135 1000 mcg/kg SC | Part 1.1: PF-06863135 Priming Cohort Q1W SC | Part 1.1: PF-06863135 Priming Cohort Q2W SC | Part 1C: PF-06863135 + Lenalidomide SC | Part 1D: PF-06863135 + Pomalidomide SC | Part 2A: PF-06863135 SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 19 |
| White | 1 | 2 | 1 | 1 | 0 | 4 | 6 | 6 | 3 | 2 | 2 | 4 | 4 | 5 | 10 | 2 | 8 | 10 | 71 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2017 to primary completion in Jan 2024, 73 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 73 months is above that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elranatamab · Dexamethasone · Lenalidomide · Pomalidomide